PA
ETON icon

PharVision Advisers’s Eton Pharmaceutcials ETON Stock Holding History

PharVision Advisers’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,535
Closed -$229K – 780
2025
Q3 		$229K Buy
+10,535
New +$175K 0.13% 398

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

PharVision Advisers's ETON Position: Q4 2025 in Review

PharVision Advisers sold out of Eton Pharmaceutcials (ETON) in Q4 2025, closing a stake of 10,535 shares — an estimated $229K sold.

PharVision Advisers first reported a position in ETON in Q3 2025 and held it in 1 quarter. The position peaked at $229K in Q3 2025. 104 funds tracked by Wall St. Rank hold ETON as of Q4 2025.

  • PharVision Advisers reported no remaining Eton Pharmaceutcials position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 10,535 Eton Pharmaceutcials shares in Q4 2025, an estimated $229K.
  • PharVision Advisers first reported a position in Eton Pharmaceutcials in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Eton Pharmaceutcials position peaked at $229K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.